📊 JAGX Key Takeaways
Is Jaguar Health, Inc. (JAGX) a Good Investment?
Jaguar Health exhibits severe financial distress with massive operating losses (-298% margin), negative cash flow (-$18.2M), and liquidity crisis (0.81x current ratio). The company is burning cash at an unsustainable rate despite modest revenue growth, with minimal equity cushion ($4.4M) and high leverage (1.43x debt/equity), indicating imminent solvency risk.
Jaguar Health shows modest top-line growth, but the quality of that growth is weak given extremely negative operating and net margins and deeply negative free cash flow. The balance sheet is fragile, with low liquidity, high leverage relative to a very small equity base, and continued losses that suggest ongoing dependence on external financing rather than internally generated cash.
Why Buy Jaguar Health, Inc. Stock? JAGX Key Strengths
- Revenue growth of 19.8% YoY demonstrates some market demand for products
- Modest improvement in net loss on a percentage basis (1.9% YoY)
- Small positive insider activity with 4 Form 4 filings in last 90 days
- Revenue grew 19.8% year over year, indicating some commercial demand expansion
- Asset base still exceeds liabilities, leaving the company with positive stockholders' equity
- Capital expenditure requirements appear low, which limits cash drain from fixed investment
JAGX Stock Risks: Jaguar Health, Inc. Investment Risks
- Critical liquidity crisis: current ratio of 0.81x indicates inability to cover short-term obligations
- Massive cash burn of $18.2M annually against only $3.5M in cash reserves signals runway of ~2 months
- Operating losses of $24.7M vastly exceed $8.3M revenue, indicating fundamentally unprofitable business model
- High debt burden ($6.2M) relative to minimal equity ($4.4M) with debt/equity of 1.43x leaves no margin for error
- Negative free cash flow of -220% FCF margin demonstrates business cannot sustain operations from operations
- Operating losses are extremely large relative to revenue, with a -298.0% operating margin
- Liquidity is tight, with a 0.81x current ratio, 0.52x quick ratio, and only $3.53M in cash
- Free cash flow and operating cash flow are heavily negative, increasing refinancing and dilution risk
Key Metrics to Watch
- Cash runway and quarterly cash burn rate
- Operating cash flow trend and path to profitability
- Revenue growth sustainability and gross margin expansion
- Debt refinancing capacity and covenant compliance
- Working capital management and accounts receivable quality
- Quarterly operating cash burn relative to cash balance
- Revenue growth versus operating loss trend
Jaguar Health, Inc. (JAGX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
JAGX Profit Margin, ROE & Profitability Analysis
JAGX vs Healthcare Sector: How Jaguar Health, Inc. Compares
How Jaguar Health, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Jaguar Health, Inc. Stock Overvalued? JAGX Valuation Analysis 2026
Based on fundamental analysis, Jaguar Health, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Jaguar Health, Inc. Balance Sheet: JAGX Debt, Cash & Liquidity
JAGX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Jaguar Health, Inc.'s revenue has grown significantly by 102% over the 5-year period, indicating strong business expansion. The most recent EPS of $-130.69 indicates the company is currently unprofitable.
JAGX Revenue Growth, EPS Growth & YoY Performance
JAGX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.1M | -$9.5M | $-6.28 |
| Q2 2025 | $2.7M | -$9.5M | $-2.66 |
| Q1 2025 | $2.2M | -$9.2M | $-16.70 |
| Q3 2024 | $2.8M | -$7.8M | $-1.05 |
| Q3 2020 | $973.0K | -$7.6M | N/A |
| Q2 2020 | $1.7M | -$9.2M | N/A |
| Q1 2020 | $869.0K | -$7.9M | N/A |
| Q3 2019 | $972.8K | -$6.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Jaguar Health, Inc. Dividends, Buybacks & Capital Allocation
JAGX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Jaguar Health, Inc. (CIK: 0001585608)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JAGX
What is the AI rating for JAGX?
Jaguar Health, Inc. (JAGX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are JAGX's key strengths?
Claude: Revenue growth of 19.8% YoY demonstrates some market demand for products. Modest improvement in net loss on a percentage basis (1.9% YoY). ChatGPT: Revenue grew 19.8% year over year, indicating some commercial demand expansion. Asset base still exceeds liabilities, leaving the company with positive stockholders' equity.
What are the risks of investing in JAGX?
Claude: Critical liquidity crisis: current ratio of 0.81x indicates inability to cover short-term obligations. Massive cash burn of $18.2M annually against only $3.5M in cash reserves signals runway of ~2 months. ChatGPT: Operating losses are extremely large relative to revenue, with a -298.0% operating margin. Liquidity is tight, with a 0.81x current ratio, 0.52x quick ratio, and only $3.53M in cash.
What is JAGX's revenue and growth?
Jaguar Health, Inc. reported revenue of $8.3M.
Does JAGX pay dividends?
Jaguar Health, Inc. does not currently pay dividends.
Where can I find JAGX SEC filings?
Official SEC filings for Jaguar Health, Inc. (CIK: 0001585608) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JAGX's EPS?
Jaguar Health, Inc. has a diluted EPS of $-22.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JAGX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Jaguar Health, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JAGX stock overvalued or undervalued?
Valuation metrics for JAGX: ROE of -696.8% (sector avg: 15%), net margin of -367.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JAGX stock in 2026?
Our dual AI analysis gives Jaguar Health, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JAGX's free cash flow?
Jaguar Health, Inc.'s operating cash flow is $-18.2M, with capital expenditures of $16.0K. FCF margin is -220.1%.
How does JAGX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -367.0% (avg: 12%), ROE -696.8% (avg: 15%), current ratio 0.81 (avg: 2).